Anna Nikonova

Chimeron Bio is an early-stage biotechnology company developing innovative, off-the-shelf therapies to transform cancer treatment. Our mission is to unlock the full potential of in vivo CAR-T by delivering multi-gene, multi-mechanism constructs directly inside the body. We aim to create potent, durable, and precise cell therapies that are both scalable and accessible. Our non-viral approach enables a new class of multiplex in vivo CAR-T treatments designed to tackle the complexity of solid tumors. In parallel, we are advancing complementary immuno-oncology programs to further our therapeutic impact. This disruptive approach has the potential to redefine the standard for cell and gene therapies in oncology.